CXCR4 and cancer: Moreover, sorafenib, a tyrosine kinase inhibitor and potent VEGF signaling suppressor approved for the treatment of different cancer types (60), was found able to inhibit endometriosis MSC proliferation, migration, and pro-angiogenic phenotype (36), while AMD3100, an antagonist of SDF-1α/CXCR4 signaling, decreased both EPC number and vascular density in murine intraperitoneal endometriotic lesions (37).